ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) Stock Price, Forecast & Analysis
BIT:1ROG • CH0012032048
1ROG.MI Key Statistics, Chart & Performance
The current stock price of 1ROG.MI is 398 EUR. In the past month the price increased by 38.19%.
1ROG.MI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to 1ROG.MI.
1ROG.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1ROG.MI. 1ROG.MI has an excellent profitability rating, but there are some minor concerns on its financial health.
1ROG.MI Financial Highlights
Over the last trailing twelve months 1ROG.MI reported a non-GAAP Earnings per Share(EPS) of 21.29. The EPS increased by 3.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.31% | ||
| ROA | 9.95% | ||
| ROE | 32.88% | ||
| Debt/Equity | 1.06 |
1ROG.MI Forecast & Estimates
For the next year, analysts expect an EPS growth of 7.31% and a revenue growth 2.76% for 1ROG.MI
1ROG.MI Ownership
1ROG.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.21 | 199.188B | ||
| SNW | SANOFI | 9.22 | 191.629B | ||
| SAN | SANOFI | 9.18 | 191.049B | ||
| MRK | MERCK KGAA | 14.87 | 54.521B | ||
| UCB | UCB SA | 27.18 | 53.237B | ||
| 1MRK | MERCK KGAA | 14.2 | 53.065B | ||
| UNC | UCB SA | 26.19 | 52.381B | ||
| 1BAYN | BAYER AG-REG | 9.41 | 45.191B | ||
| BAYN | BAYER AG-REG | 9.41 | 44.887B | ||
| IPN | IPSEN | 13.56 | 12.37B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1ROG.MI
Company Profile
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Company Info
ROCHE HOLDING AG-GENUSSCHEIN
Grenzacherstrasse 124
Basel BASEL-STADT CH
Employees: 103249
Phone: 41616881111
ROCHE HOLDING AG-GENUSSCHEIN / 1ROG.MI FAQ
Can you describe the business of ROCHE HOLDING AG-GENUSSCHEIN?
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
What is the current price of 1ROG stock?
The current stock price of 1ROG.MI is 398 EUR. The price increased by 6.42% in the last trading session.
What is the dividend status of ROCHE HOLDING AG-GENUSSCHEIN?
ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) has a dividend yield of 2.7%. The yearly dividend amount is currently 11.01.
What is the ChartMill rating of ROCHE HOLDING AG-GENUSSCHEIN stock?
1ROG.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the Price/Earnings (PE) ratio of ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI)?
The PE ratio for ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) is 18.69. This is based on the reported non-GAAP earnings per share of 21.29 and the current share price of 398 EUR.
What is the market capitalization of 1ROG stock?
ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) has a market capitalization of 322.08B EUR. This makes 1ROG.MI a Mega Cap stock.
What is the ownership structure of ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI)?
You can find the ownership structure of ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) on the Ownership tab.